Home / Pharmaceutical industry / Cradle
Cradle (Amsterdam, Netherlands and Zürich, Switzerland)Cradle
AI platform for protein design: generates and optimises candidates for antibodies, enzymes, vaccines and peptides, and learns from lab results round by round.
Spot1of 13 professional tools on GDPR profileOur summary of what the provider itself publishes about your data: whether the data is held in the EU (2 points), whether there is a certification or GDPR guarantee (1) and whether the provider is established in the NL or the EU (1). 3 or 4 points is Strong, 2 Good, 1 Limited, 0 Unknown. How we measure in pharmaceutical industry
GDPR: Strong
- Provider based in the Netherlands
- Data in the EU according to the provider
- Publishes certification/GDPR safeguards
Priceon request (no royalties or milestone payments)on request (licence, no royalties or milestone payments)
Free trialNone foundNot found on the provider's site when checked on 2 November 2026
Based inAmsterdam, the Netherlands and Zürich, Switzerlandthe Netherlands
ModelNot publicproprietary protein models, trained per client. Hosted on Google Cloud in the Netherlands (europe-west4) with replication within the EU; Cradle never combines or shares data or models between clients. SOC 2 Type II, ISO 27001 in preparation; data processing agreement (DPA) available.
Last checked: 2 November 2026 · How we check
Is this your tool? Fill in missing detailsWhat it does
Design protein candidates
Optimise properties in parallel
Learns from your own lab data each roundAntibodies, enzymes, vaccines, peptides
Web app with point-and-click design
All features also available via APIComparable in pharmaceutical industry
Biolevateon request
Castoron request
Aily Labson request
Causalyon request (enterprise, via demo)
Owkin K Proon request
Ardigenon requestCradle compared
Underlying model
GDPR check for pharmaceutical industry proprietary protein models, trained per client. Hosted on Google Cloud in the Netherlands (europe-west4) with replication within the EU; Cradle never combines or shares data or models between clients. SOC 2 Type II, ISO 27001 in preparation; data processing agreement (DPA) available. Many tools build on a large model from providers such as OpenAI or Anthropic. If in doubt, ask for the data processing agreement: it sets out where your data goes.
Questions about Cradle
- Which AI model does Cradle use?
- The maker of Cradle does not make public which AI model sits underneath. Proprietary protein models, trained per client. Hosted on Google Cloud in the Netherlands (europe-west4) with replication within the EU; Cradle never combines or shares data or models between clients. SOC 2 Type II, ISO 27001 in preparation; data processing agreement (DPA) available.
- How much does Cradle cost?
- On request (licence, no royalties or milestone payments). Check the current price on the provider's website; rates change often.
- Who is Cradle for?
- Cradle is aimed at pharmaceutical industry, research & science. It fits work such as finding and optimising targets, proteins and candidate molecules with AI models, setting up clinical studies: recruiting patients, capturing source data and monitoring data quality, and drafting regulatory documents (protocols, CSRs, dossiers) with traceable sources.
- What should I look out for with AI in the pharmaceutical industry?
- This sector involves health data of trial participants and patients (special category personal data under Article 9 GDPR) and confidential research data. Ask every provider where the data is stored and whether it is used to train models: Castor hosts in the Netherlands (Google Cloud europe-west4) and does not share data or models between customers, Cradle states that source data never goes to third-party AI models, Iris.ai hosts on AWS in Ireland and Germany. Biolevate and Ennov also run in private cloud or on-premises. With Veeva Vault AI and Yseop, texts go to Anthropic models via Amazon Bedrock; check the region and the data processing agreement. If you work in GxP processes, an AI tool must also be validated (EU GMP Annex 11) and a competent employee remains responsible. For AI in medicines development, the EMA has a reflection paper (2024) and is working with the FDA on joint principles.
Every Friday: what changed in AI for the pharmaceutical industry
New models, prices, oversight and tools, with sources and what it means for you. One email a week, unsubscribe with one click.